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Aurora kinases are key regulators of chromosome segregation during mitosis. We have previously shown by microarray analysis of
primary lung carcinomas and matched normal tissue that AURKB (22 out of 37) and AURKA (15 out of 37) transcripts are frequently
over-represented in these tumours. We now confirm these observations in a second series of 44 carcinomas and also show that
aurora B kinase protein levels are raised in the tumours compared to normal tissue. Elevated levels of expression in tumours are not a
consequence of high-level amplification of the AURKB gene. Using a coding sequence polymorphism we show that in most cases
(seven out of nine) tumour expression is predominantly driven from one AURKB allele. Given the function of aurora B kinase, we
examined whether there was an association between expression levels and genetic instability. We defined two groups of high and
low AURKB expression. Using a panel of 10 microsatellite markers, we found that the group showing the higher level of expression
had a higher frequency of allelic imbalance (P¼0.0012). Analysis of a number of other genes that are strongly and specifically
expressed in tumour over normal lung, including SERPINB5, TERT and PRAME, showed marked allelic expression imbalances in the
tumour tissue in the context of balanced or only marginally imbalanced relative allelic copy numbers. Our data support a model of
early carcinogenesis wherein defects in the process of inactivation of lung stem-cell associated genes during differentiation,
contributes to the development of carcinogenesis.
British Journal of Cancer (2005) 93, 719–729. doi:10.1038/sj.bjc.6602779 www.bjcancer.com
& 2005 Cancer Research UK
Keywords: lung cancer; aurora; genetic instability; stem cells
                                                     
Lung cancer is the leading cause of cancer-related death (Shibuya
et al, 2002). Although a small proportion of tumours are sensitive
to existing cytotoxic or targeted therapies (Lynch et al, 2004), most
are resistant to current anticancer treatments. While surgical
resection may be curative for a limited number of non-small cell
carcinoma (NSCLC) patients, most disease is overtly or covertly
metastatic at presentation and consequently, currently incurable.
The development of more widely effective targeted agents is
therefore necessary not only to improve the treatment of advanced
stage nonresectable disease but also to complement future
screening capabilities in the areas of secondary and tertiary
disease prevention (chemoprevention).
An important step in the rational identification of novel drug
targets for such treatments lies in an understanding of the gene
expression pattern of the tumour cell and how that pattern relates
to other normal cells. We have therefore compared transcript
levels in a range of primary lung tumours relative to their matched
normal tissue through a comprehensive microarray analysis. This
has facilitated the construction of ranked lists of genes, the
transcripts of which are frequently and dramatically over-
represented in tumours compared to matched normal lung tissue
(Heighway et al, 2002). As most lung carcinomas arise from a
minority component of the tissue – the epithelial lining of the
bronchial airways – many tumour over-represented transcripts in
our analysis will likely reflect appropriate gene expression in the
progenitor cell, wherever that expression is not typical of the
differentiated cell majority. The comparison of tumour to normal
lung tissue is therefore likely to be an effective way to identify
potentially targetable gene products that are not commonly active
in the bulk of normal cell types.
Inappropriately upregulated (or gain of function somatically
mutated) sequences are likely to make the most effective drug
targets. If we further assume that such upregulation is often
associated with localised genetic or epigenetic damage, then one
approach to identify potentially targetable genes that are Received 11 April 2005; revised 20 July 2005; accepted 11 August 2005
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spathologically miss-regulated is to compare the allele-specific
levels of gene expression in tumour and normal tissues (Ratschiller
et al, 2003). If there is no imbalance – if transcription is driven in
the tumour cell equally from both parental alleles – then such
expression is not likely to be the direct result of localised damage
(although it could be a direct consequence of damage at a trans
site). Conversely, where alleles are balanced in genomic DNA, the
identification of allelic expression imbalance (AEI) in tumours, but
not matched normal tissue (Smith et al, 2004), indicates that the
increased level of expression for a given candidate may not be a
consequence of the normal regulatory processes governing the
activity of that gene.
It has been considered likely that lung cancer arises from a stem
cell or multipotent component of the bronchial epithelium. Indeed,
tumours often appear to share the expression patterns of specific
genes with multipotent cells of the airway (Massion et al, 2003;
Smith et al, 2003, 2004). By analogy with other solid tumours
(Al-Hajj et al, 2003; Singh et al, 2003), it is possible that such a
stem cell or stem cell-like tumour initiating component is a
minority population within the neoplastic lesion. Such an
argument is supported by in vitro data, for example; only one in
1000–5000 lung cancer cells were found to form colonies in soft
agar (Hamburger and Salmon, 1977). Although it might be argued
therefore that the analysis of gene expression in the bulk of the
tumour mass might be an inefficient way to identify differentially
expressed transcripts associated with such a minority component,
it nevertheless remains likely that elemental, DNA damage-driven,
pathological, stem cell expression patterns will be represented
throughout the tumour mass. Indeed, in the context of therapy, it
could be argued that the most important new drug targets are
likely be constitutively and abnormally activated in both the stem
cell progenitors and the aberrantly differentiated progeny. Such
inappropriately expressed genes may be detected by microarray or
other expression analyses of tumour against normal tissue.
In our earlier genome-wide microarray analysis, we identified
the aurora B kinase gene (AURKB) as differentially expressed in a
high frequency (42-fold in 59%, 22 out of 37 cases) of primary
NSCLC (Heighway et al, 2002). Aurora B kinase, a candidate drug
target undergoing preclinical and clinical validation (Keen and
Taylor, 2004), is thought to facilitate the correct alignment of
chromosomes on the metaphase plate by actively destabilising
mono-polar spindle attachments (Dewar et al, 2004). Our aim was
to investigate whether aurora B kinase deregulation occurs in lung
cancer. Specifically, it was our intention to confirm the microarray
data suggesting strong tumour cell expression, then to investigate:
whether high levels of expression were driven from one or both
parental alleles in tumours and normal tissue, whether AURKB was
amplified in NSCLC and to determine whether AURKB expression
was associated with the level of genetic instability within tumours
and patient survival.
METHODS
Clinical samples and cell lines
RNA and DNA was extracted from tumour and matched normal
lung (NSCLC) tissue samples from 48 Swiss patients (for expression,
AEI and genetic instability analysis) and a smaller number (37
patients for AEI analyses) of Liverpool patients (Smith et al, 2003,
2004) as part of wider ethically approved studies of gene expression
in bronchial tissues – cDNA synthesis from the extracted total RNA
was also carried out as described previously (Heighway et al, 2002).
Normal human bronchial epithelial cells (NHBE5239) were obtained
from Clonetics and cultured according to the manufacturer’s
instructions in BEGM-Bronchial Epithelial Medium (Clonetics).
Cells (1 10
7) were split into two flasks and after further growth,
were subsequently harvested in either an exponential or confluent,
growth arrested state (each flask after different lengths of time in
subculture). Total RNA was extracted from these parallel cultures
using a standard Trizol protocol and cDNA synthesised as for
primary tissue as described in Heighway et al (2003).
Comparative multiplex RT–PCR
Comparative multiplex RT–PCR was used to compare levels of test
gene transcripts between normal lung and tumour samples, as
described previously (Heighway et al, 2002). The test gene
transcript (AURKB) was coamplified with a nondifferentially
expressed control transcript (APPBP2 – KIAA0228) in 30 cycle
RT–PCR reactions. Products were run on 3% agarose gels
containing 0.5mgml
 1 ethidium bromide, in 0.5  TBE and
visualised by UV illumination. Relative expression was quantified
on an Agilent 2100 Bioanalyser using DNA 1000 LabChips
s
(Agilent Biotechnologies). The peak height of the test gene was
divided by that of the control gene within each sample. The
comparative value in the patient tumour tissue was then divided by
that from the matched normal to calculate the fold difference in
expression of the test gene in each patient. For the purpose of this
analysis, differential expression of the test gene of X2-fold in the
tumour was arbitrarily considered to indicate a relative over-
representation of that gene in the tumour. Primers used for
APPBP2 were 50 gaactgtgtgcactcctatttg and 50 ccgtgccaaatacactg
catgt and for AURKB, 50 cagagagatcgaaatccaggc and 50 ccttgagccc
taagagcagat. Primers were confirmed to be cDNA specific by test
amplifications of genomic DNA.
Allelic imbalance (AI) and AEI analysis
Allelic (im)balance relates to the genomic balance of the two
parental alleles in a DNA samples; allelic expression (im)balance
refers to the relative levels of expression of each of those alleles in a
cDNA sample. A tissue may therefore show allelic balance but AEI
if one parental allele is expressed more strongly than the other.
Measurements of AI and AEI were carried out using single-
nucleotide polymorphisms (SNPs) localised with the mRNA
coding region of each specific gene (cSNPs) in simple PCR (AI)
and RT–PCR (AEI) restriction fragment length polymorphism
(RFLP) assays. Single-nucleotide polymorphisms were selected
from public domain databases and validated in PCR-RFLP assays
of DNA extracted from normal lung tissue. Exon-spanning primers
were designed around the SNP and confirmed to be cDNA-specific
in test amplifications. Subsequently, the patient population
(normal DNA) was scanned to identify informative (heterozygote)
individuals. Allelic balance in normal and tumour DNA, and in
normal (where a product was amplifiable) and tumour cDNA was
measured for each informative patient.
AURKB A nonsynonymous C/T (Thr/Met) polymorphism in
exon 9 (nt 950 in NM_004217) creates a natural NcoI RFLP,
with the T (CCATGG) but not the C (CCACGG) allele cleaved by the
restriction enzyme. DNA specific (50 cagaatgggtagtcaaggaag and
50 gcgacagattgaagggcagag) or cDNA specific (50 caacgagacc
tatcgccgc and 50 gcaccctccgagagttggccc) primer pairs were used
in 25ml PCR (or RT–PCR) reactions containing 1ml (0.1mg) of
genomic DNA (or 1ml of cDNA), 0.25ml of each primer
(0.5mgml
 1) and 12.5ml of Qiagen HotStarTaq Master Mix and
11mlo fd H 2O. Reactions were cycled at 951C for 15min, 30 (RT–
PCR, 35) cycles of (941C for 30s, 581C for 90s, 721C for 90s)
followed by 30min at 601C in a Biometra T3 Thermocycler.
Products were visualised on 2.5% agarose gels.
RFLP-PCR and RFLP-RT–PCR analyses:A3 ml aliquot of each
PCR product (B0.5mg) was digested with 3U of restriction
endonuclease in 20ml reactions at 371C for 5h. Digests were
visualised by gel electrophoresis and relative allelic expression
quantified by running 1ml aliquots of the digest on an Agilent 2100
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s.
Ratios of the peak height of the smaller cut band (corresponding
to the T allele) to the larger uncut band (corresponding to the C
allele) for each of the heterozygous genomic DNA and cDNA
samples were calculated. The mean and the standard deviation of
the values for the normal genomic DNA samples and the normal
cDNA samples were determined, and tumour genomic DNA and
the tumour cDNA samples that deviated by more than three
standard deviations (s.d.) from the mean of the corresponding
normal samples were scored as showing AI or AEI.
SERPINB5 A nonsynonymous A/G (Iso/Val) polymorphism in
exon 7 (nt 1022 in NM_002639) creates a natural Hpy8I RFLP with
the G (GTCCAC) but not the A (ATCCAC) allele cleaved by the
restriction enzyme. DNA (50 gtggactaatcccagcaccat and 50 ctatg
gaatccccaccatcttc) and cDNA specific 50 cagtgcagatgatgaacatgg and
50 ctatggaatccccaccatcttc primers were used in PCR/RT–PCR
reactions with the conditions described for AURKB. Reaction
products were digested as described but using only 0.5U of
enzyme/reaction for 5h. Allelic ratios were determined as for
AURKB but as so few normal lung cDNAs gave an analyzable
product, both AI and AEI were scored with reference to the mean
and s.d. values of normal DNA digests.
PRAME A nonsynonymous A/G (Trp/Arg) polymorphism in
exon 3 (nt 305 of NM_206956) generates a natural FauI RFLP with
the G (CCCGC) but not the A (CCCAC) allele cleaved by the
restriction enzyme. DNA (50 caggaggccgttgcttcgta and 50 cgtctactgt
gagggacctc) and cDNA specific (50 cagtgcagatgatgaacatgg and
50 ctgccagctccacaagtctc) primers were used in PCR/RT–PCR
reactions with the conditions described and digests carried out
using 0.6 enzyme units/reaction at 551C for 5h. AI and AEI were
scored as for SERPINB5.
TERT A synonymous (A/G) polymorphism in exon 2 (nucleotide
970 of AF015950) creates a natural Psp0M1 RFLP with the G
(GGGCCC) but not the A (AGGCCC) allele cleaved by the
restriction enzyme. DNA primers (50 cgaagaagccacctctttggag and
50 cagggagatgaacttcttggtgt) were used in standard PCR reactions
and products digested with 3 enzyme units/reaction at 371C for 3h.
Tumour AI was scored by visual comparison with normal DNA
products. Given the apparently low levels of telomerase mRNA in
primary tumour tissue, a nested protocol was used for RT–PCR.
Initial products (38 cycles with 50 cgaagaagccacctctttggag and
50 tacacactcatcagccagtgca) were diluted 1/50 and a 1ml aliquot
reamplified with internal primers (50 tttggagggtgcgctctctg
50 caggatctcctcacgcagac). Products were digested as for DNA. Only
one allelic band was visible in tumour RT–PCR products and so
relative quantitation was not attempted.
Western analysis
Western analysis of protein extracts of tumour and normal lung
tissue were carried out essentially as described (Smith et al, 2003).
Equal amounts of protein from matched tumour and normal tissue
were loaded per lane. Protein was detected using mouse
monoclonal anti-Aim-1 antibody (1:500 dilution; BD Transduc-
tion Laboratories) and goat anti-mouse HRP-conjugated second-
ary antibody (1:2000; Dako). Detection was performed using the
ECL Plus Western Blotting Detection System (Amersham).
Quantitative real-time RT–PCR
Gene expression relative to the nondifferentially expressed con-
trol gene, APPBP2 was measured using Applied Biosystems
(AB) predesigned TaqMan cDNA-specific assays: for APPBP2
(Hs00197271_m1), AURKB (Hs00177782_m1), AURKA
(Hs00269212_m1) and SERPINB5 (Hs00184728_m1). It should be
noted that the real time assays measured expression at a different
point within the cDNA to the comparative multiplex assays.
Triplicate 20ml RT–PCR reactions for each sample containing:
10ml of AB TaqMan Universal PCR Master Mix, 1ml of the relevant
20  assay, 1ml of target cDNA and 8mlo fd H 2O were cycled at
501C for 2min, 951C for 10min and 45 times at 951C for 15s, 601C
for 1min on an AB 7500 Real Time PCR System. CT values were
calculated using the 7500 SDS software. AURKA and AURKB gene
expression for each sample was normalised to control gene
expression and fold difference between tumour and normal tissue
were calculated using the DDCT method (Applied Biosystems User
Bulletin #2, 1997).
Quantitative real time PCR
Relative gene copy number was quantified using the DDCT of test
and control genes in amplifications of normal and tumour tissue
derived DNA. Control loci which in our experience do undergo
gene amplification or homozygous deletion in primary lung
carcinomas were selected. For the initial analysis, the MGMT
locus was used (10q26.3 – defined by NM_002412). Taqman PCR
assays were designed for this locus, a second control region
(gamma globin – HBG, 11p15.4, locus defined by X55656) and for
the test gene: AURKB, using Applied Biosystems Primer Express
v2.0 software and standard parameters. Triplicate PCR reactions
for each sample containing 20ml of AB TaqMan Universal PCR
Master Mix, B200ng of genomic DNA, PCR primers (1mM) and a
TaqMan probe (250nm) in a total of 40ml were cycled under the
standard AB conditions detailed above. The DCT between the
AURKB and MGMT amplifications were calculated for each
tumour and compared to a mean DCT derived from 20 normal
lung DNA samples. Tumour samples with DCT values greater than
the normal mean73 standard deviations were considered to show
significant shifts in relative gene copy number from normal DNA.
Subsequently, for a small number of samples a DDCT value was
calculated by comparing tumour DNA to its matched normal
tissue derived DNA. Primer sequences used were, for MGMT, 50
gcagggtaacgcatagccttac and 50 tcgcagcacactgttttgaga with a TaqMan
probe of 50 6-FAM cacaaccgcaaccacgagtccgt TAMRA 30; AURKB,
50 tccctgttcgcattcaacct and 50 gtcccactgctattctccatcac with a Taq-
Man probe of 50 6-FAM ctgttctctccttagctgcccctggc TAMRA 30; HBG
50 gcccttgtggatgcctaaga and 50 gtctctcccttgaaatgctgtga with a
TaqMan probe of 50 6-FAM cccatgccctcaagtgtgcagattg TAMRA.
Multiplex microsatellite analysis
Proprietary PCR primers for the microsatellite loci D3S1263,
D3S1300, D3S1566, D5S644, D9S157, D9S161, D13S153, D13S171,
D13S263, D17S938 were selected from Applied Biosystems linkage
sets. These markers have previously been shown to show
consistent allelic imbalance in lung carcinoma samples (Liloglou
et al, 2001). For each locus the forward primer had 50 fluorescent
modification and the reverse primer had a 50 biotin modification
Multiplex PCR reactions (10ml) containing 2ml (0.2mg) of genomic
DNA were cycled on a Biometra T3 Thermocycler. In addition
to target DNA, each reaction contained following primers:
D3S1263 (2.5pmol), D3S1300 (2pmol), D3S1566 (1pmol),
D5S644 (2.2pmol), D9S157 (5pmol), D9S161 (1.7pmol), D13S153
(2pmol), D13S171 (2pmol), D13S263 (2pmol), D17S938 (4pmol);
5ml of Qiagen Multiplex PCR Kit Master Mix and 2mld H 2O.
Cycling conditions were 951C for 15min, 30 cycles (941C for 30s,
561C for 90s, 721C for 60s) followed by 30min at 601C.
PCR products were purified using 2ml Dynabeads
s M-280
Streptavidin and resuspended in 4ml of loading buffer (10:2:1
formamide, dextran blue/EDTA, ROX 400HD size standard).
Samples were denatured at 951C for 5min, chilled on ice and
1ml was loaded on a 5% denaturing polyacrylamide gel on a 377
ABI sequencer. The gel image was analysed using the ABI
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sGenescant and Genotypert software. Allelic imbalance was
scored according to previously established performance criteria
if the allelic ratio (A1/A2 tumour)/(A1/A2 normal) was outside a
range of 1.25–0.75 (Liloglou et al, 2000). Assays were carried out
in duplicate and AI scored only if both results for an individual
sample were outside the normal range.
Statistical analyses
Comparisons were carried out using a 2 2 contingency table
running two-tailed Fisher’s exact tests (GraphPad). For associa-
tions with survival, patients were further placed into two groups
according to their AURKB expression levels (real-time). Survival
differences were analysed using Kaplan–Meier survivor function
estimators and log-rank test (StatView software version 5.0.1 SAS
Institute Inc., Cary).
RESULTS
AURKB expression in tumours and patient survival
In addition to the noted over-representation of AURKB transcripts
in NSCLC, further analysis of the original gene expression array
data set (Heighway et al, 2002) indicated that AURKA transcripts
were also over-represented, but to a lesser extent, in 15 out of 37
cases. AURKC was not scored as over-represented in any tumour
(0 out of 37) (data not shown). Using comparative multiplex
RT–PCR (cmRT–PCR) in a second series of patients, we were able
to confirm that the observed differential expression events were in
fact common in primary lung carcinomas (Figure 1). Expression of
AURKB was detected by RT–PCR in 44 NSCLC and matched
normal lung samples (four Swiss samples gave no usable cDNA
following attempted RT–PCR). Using a nondifferentially ex-
pressed control gene (APPBP2), cmRT–PCR was used to quantify
the degree of relative AURKB expression between the normal and
tumour tissues for each patient (Figure 1, Table 1). Using an
arbitrary threshold of two-fold or above, 93% (41 out of 44)
tumours showed over-representation of this transcript relative to
normal lung. Elevated levels of aurora B kinase protein were
confirmed in representative matched tumour and normal tissue
samples by Western analysis (Figure 1).
In a confirmation of the cmRT–PCR data, Taqman real-time
DDCT quantitative RT–PCR (qRT–PCR) was used to examine the
expression of AURKB relative to APPBP2 in the same 44 samples
(Table 1). This analysis again confirmed that AURKB was
commonly strongly expressed in the majority of primary NSCLC
tissues compared to matched normal tissue (39 out of 44; 89%,
showed a two-fold or greater overexpression). Although real-time
qRT–PCR is more sensitive than cmRT–PCR, and can therefore
measure differential expression in paired samples where expres-
sion is at very low absolute levels, there was a good general
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Figure 1 Representative examples of comparative multiplex RT–PCR
analyses of matched normal and tumour tissue (A) and normal human
bronchial cells (B) are shown. (C) A Western analysis confirming strong
differential expression of aurora B kinase between tumour and matched
normal tissue in five tumours. Although approximately equal amounts of
protein were loaded, absolute aurora B kinase levels, while clearly higher in
tumour in each case, do not appear in all cases to show a close relationship
to relative transcript levels.
Table 1 Expression data and sample details: Patients are ranked
according to the comparative multiplex RT-PCR values for AURKB
(column 2)
Aurora B
Aurora A
Patient cmRT-PCR Real time Real time Gender Age Tumour type
195 0.3 0.4 37 M 65.4 Squamous cell
179 0.8 1 0.9 M 47.8 Squamous cell
187 1 1 F 51.8 Adeno
206 2 1 0.6 M 59.5 Squamous cell
210 2 5 23 M 52.6 Adeno
223 2 5 6 M 67.2 Adeno
173 3 2 50 M 73.4 Adeno
182 4 4 9 M 69.5 Squamous cell
176 4 5 2 F 57.4 Adeno
231 6 17 0.07 M 72.5 NSCLC
232 6 7 0.5 M 74.3 Adeno
184 6 3 8 F 39.2 Adeno
211 6.8 1 2 M 71.5 Adeno
208 7 4 6 M 47.6 Squamous cell
205 8 11 3 M 73.3 Squamous cell
216 8 10 6 M 57.7 Squamous cell
217 9 11 F 69.5 Adeno
237 12 12 M 79.5 Squamous cell
224 13 19 M 68.5 Squamous cell
222 13 21 M 54.6 Adeno
226 14 16 F 62.6 Adeno
186 15 14 M 68.5 Adeno
227 16 17 M 74.8 Squamous cell
214 16 39 F 69.7 Adeno
236 17 20 F 80.6 Adeno
189 17 17 F 57.1 Adeno
233 18 18 F 50.4 Adeno
218 19 18 M 72 Adeno
235 27 42 0.001 M 65.6 Large cell
198 28 29 65 M 74.6 Squamous cell
194 29 14 14 M 68.9 Squamous cell
229 29 16 0.1 M 80.7 Adeno
193 30 21 7 M 74.8 Squamous cell
200 32 42 34 M 62.6 Adeno
207 36 721 2589 M 63.3 Squamous cell
183 40 53 25 M 63.7 Adeno
174 42 65 40 M 49.6 LCNEC
209 44 30 125 M 55.7 Squamous cell
204 47 81 22 M 58 Squamous cell
197 64 25 14 M 54.7 Squamous cell
230 76 108 40 M 70.1 Squamous cell
220 80 105 12 M 76.2 Squamous cell
175 144 85 — F 65.2 Adeno
196 189 53 7 M 52.9 Adeno
The corresponding real time values are listed in column 3 and the AURKA real time
data for the two groups analysed for genetic stability are given in column 4. Values are
fold-change in the tumour relative to patient matched normal tissue, normalised by
APPBP2 levels.
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sagreement between the two approaches (Table 1). Survival ana-
lysis of the 39 out of 44 patients with AURKB overexpression
(relative expression X2 according to the real-time PCR data) were
preformed using Kaplan–Meier method and log-rank test
(Table 1). A threshold of 45.8 was defined, representing the mean
AURKB expression value, dividing the patients into a group with
excessive AURKB overexpression and moderate AURKB over-
expression. Progression-free survival was significantly shorter
for patients with excessive AURKB overexpression (P¼0.028)
(Figure 2), whereas overall survival was not statistically different
(P¼0.153) (data not shown).
In order to determine whether the elevated expression of aurora
B kinase was a normal characteristic of proliferating bronchial
cells, we firstly examined AURKB expression levels in a primary
cell culture model under different conditions. The early-passage
primary culture was split into two flasks and the cells were allowed
to grow for different lengths of time. From the first flask, RNA was
isolated when the population was subconfluent and the cells in
exponential growth. In the second parallel flask, the cells were
grown to confluence and held for 2 days in this state before RNA
was isolated. Using comparative multiplex (Figure 1) and real time
qRT–PCR, we were able to demonstrate that AURKB was
expressed strongly in proliferating normal primary bronchial
epithelial cells, but that this expression was strongly down-
regulated in quiescent cells (B4000-fold; DDCT of 12 cycles).
AURKA expression was also reduced in confluent relative to
exponentially growing cells but to a lesser extent (B50-fold, DDCT
of 5.6 cycles). In each case APPBP2 was used as the qRT–PCR
control gene. This raised the possibility that the strong expression
of AURKB seen in tumours was merely a consequence of the
higher proliferative state of tumour over normal tissue. If this were
the case, then it might be expected that both parental alleles would
be expressed equally in tumour tissue. We therefore examined
whether expression of the gene in both normal and tumour tissue
was allelically balanced.
AURKB AEI
Nine patients (nine out of 44, 20%) were heterozygous for a
nonsynonymous cSNP in exon 9 of the gene. Using PCR-RFLP and
RT–PCR-RFLP analyses, we were able to show that relative to the
patient matched normal cDNA, seven out of nine of these samples
showed a marked AEI favouring one or other AURKB allele
(outside the range of mean allele ratio in normal tissue73s.d.). In
six out of seven of these cases, this AEI was associated with a
phase-matched allelic imbalance in the tumour DNA (Figure 3).
The allelic ratio in the matched normal samples suggested that
both alleles were genomically balanced and expressed equally in
each patient.
AURKB copy number analysis
Elevated gene expression for AURKA is associated in a number of
tumours with high-level amplification of the gene (Sen et al, 1997;
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Figure 2 Progression-free survival of the 39 NSCLC patients with
AURKB overexpression (relative expression X2) according to the real-
time PCR data presented in Table 1. A threshold of 45.8, representing the
mean expression value of these patients, was used to separate patients into
two groups, representing excessive (n¼8) and moderate (n¼31) AURKB
overexpression. The Kaplan–Meier method and log-rank test was used.
TNTNTNTNTNTNTNTNTN
TNTNTNTNTNTNTNTNTN
| 184 |   197 | 200 | 209 | 210 | 224 | 226 | 232 |  236 |
DNA
cDNA
A1
A2
A2
A1
M
M
3 25 42 30 5 19 16  7 20
Allelic imbalance Allelic expression imbalance
Figure 3 AURKB allele-specific expression analyses and corresponding allelic imbalance measurements in matched primary tissues from lung cancer
patients. Most tumour samples showed expression strongly biased towards one allele. This is frequently accompanied (six out of seven) by a marginal allelic
imbalance in the genomic DNA. The marker track (on all gel images) is a ØX174 HaeIII digest. Bands representing parental alleles are marked A1/A2.
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levels of expression of AURKB in lung cancer might also be related
in some instances to high-level gene amplification. All tumour
DNA samples were therefore scanned for such events by
quantitative real time PCR. Using the MGMT locus on 10q26.3
as a genomic control, the mean DCT (AURKB-MGMT) for 24
normal lung DNA samples was 0.4 with a range of 0.6 cycles. The
mean DCT for the 48 tumour DNA samples was significantly
different at  0.3 (Student’s t-test, Po3 10
 11) and the range (2.2
cycles, maximally 4.5-fold copy number difference) was wider,
suggesting that a number of the tumour samples had marginal
increases in AURKB copy number. The DCT of 17 out of 48 tumour
DNA samples were outside the normal sample DCT mean 3s.d.
(indicating a small but significant relative over-representation of
AURKB in these cases).
Taken together, these data suggest firstly that no tumour
samples show high level amplification of the AURKB gene and,
secondly, that a large number of tumours show apparent low
level increases in gene copy number. Although we have no data
suggesting that the MGMT locus undergoes homozygous deletion
in NSCLC cells (an alternative possibility which would also explain
our copy number data), we repeated the analysis on two samples
showing apparently low levels of AURKB amplification using a
second locus on a different chromosome as a control. Two samples
(224, a tumour showing marginal allelic imbalance for AURKB,
and 230) were analysed with their matched normal tissue and a
formal DDCT calculated against both control genes. The second
genomic locus (HBG on 11p15.4) in this analysis also acted
therefore as a control for MGMT stability. In both cases, the qPCR
data suggested a low-level over-representation of the AURKB
genomic locus in the tumour DNA relative to control levels:
patient 224:1.9 and 1.7-fold and patient 230:2.9 and 2.5-fold
(against MGMT and HGG1, respectively). These results therefore
confirm that the MGMT locus is not affected by copy number
differences in these tumours. The data also thereby confirm an
increase in AURKB copy number has occurred in these tumours
and further suggest that the allelic imbalance in case 224 was a
consequence of additional copies of one allele and not deletion of
the other in a subpopulation of tumour cells.
Association of genetic instability with AURKB expression
In vitro data have indicated that the forced expression of aurora B
kinase in Chinese hamster embryo cells is associated with
increased expression of histone H3 and subsequent anueploidy
(Ota et al, 2002). We therefore tested whether tumours with high
levels of AURKB expression showed higher levels of genomic
instability than those expressing low levels of the gene. Tumours
were ranked initially according to their expression of AURKB as
determined by comparative multiplex RT–PCR. The 16 highest
and lowest expressing lesions were selected for analysis. One
tumour DNA in each group was resistant to PCR amplification
under the protocol used and so was excluded. A 10 marker
microsatellite panel comprising loci previously shown to be highly
informative and frequently imbalanced in lung carcinomas was
used in multiplex analyses to amplify tumour and normal DNA
from the 30 patients. Allelic imbalance for each marker, for each
tumour, was scored according to previously defined criteria. The
number of informative cases in each group showing either allelic
imbalance or no allelic imbalance was totaled and the values
compared between the two groups using a Fisher’s exact test
(Table 2). Tumours showing high levels of expression showed a
highly significant excess of allelic imbalance (67 loci imbalanced vs
54 balanced) over those with low-level (42 imbalanced vs 81
balanced) expression (P¼0.0012). To confirm this conclusion,
these 30 cases were reranked using the Taqman qRT–PCR data
(Table 1). While data were broadly similar, the real-time rankings
resulted in the reciprocal movement of two cases between groups
(194 and 231). Following this adjustment, the difference in overall
allelic imbalance between the two groups was more marked (71 vs
50, 38 vs 85, respectively, P¼0.0001).
Our earlier microarray analysis had indicated that AURKA was
also frequently over-represented in primary NSCLC. Mindful of the
suggestion of Keen and Taylor (2004) that AURKA and AURKB
were generally coordinately expressed in human tumours, we
analysed the expression levels of AURKA in the 30 patient series
analysed for genetic instability by real time quantitative PCR.
Although we were broadly able to affirm the conclusion of
coordinate expression, there were clearly a number of tumours
that expressed strongly one or other gene (Table 1). The 30 cases
analysed for genetic instability were reranked according to AURKA
expression and divided into two groups of low and high
expression. The association of allelic imbalance observed with
AURKB expression was no longer present in these AURKA-ranked
groups (Table 2: 57 vs 66, 52 vs 69, P¼0.8).
AEI in other tumour-associated genes
Our previous analyses of the expression of two genes that are
strongly expressed in tumours have suggested that these sequences
are normally expressed in multipotent components of the
bronchial airway (Smith et al, 2003, 2004). Given our observation
of the overexpression of aurora B kinase and the suggestion that
such expression might cause aneuploidy through chromosome
miss-segregation, we analysed the allelic expression balance of a
number of NSCLC associated sequences. The sequences chosen
were generally amplifiable by RT–PCR only from tumour tissue,
although we have shown that SERPINB5 is expressed in the normal
airway basal cell (Smith et al, 2003). Both AEI and AI were
measured in a series of informative patients using mRNA-encoded
cSNPs for SERPINB5 (encoding maspin), TERT (encoding a
telomerase subunit) and PRAME (encoding a tumour antigen of
unknown function with a highly restricted normal tissue expres-
sion pattern (Heighway et al, 2002). In each case, we were able to
identify high levels of AEI (Figure 4). For SERPINB5, AEI was seen
in 15 out of 25 (60%) of informative tumours, 11 of which showed
a phase-matched allelic imbalance. Four tumours in the series
therefore demonstrated stronger expression from one parental
allele in the apparent absence of AI. In a small number of cases
only (5), it was possible to amplify maspin from matched
histologically normal bronchial tissue. These cases may therefore
represent an abnormal situation. In three of these samples, the
cDNA showed AEI in the absence of phase-matched AI. In one case
(230), tumour and normal tissue from the same patient showed
phase miss-matched AEI. Allelic expression imbalance was also
common (16 out of 18 samples) in tumours that expressed
PRAME. Marginal (distinctive in one) AI was detected in nine out
of 16 of those samples and in one cases, this marginal imbalance
was phase miss-matched with the expression imbalance. Most
dramatically, in the five out of five informative tumours where we
were able to amplify the TERT cSNP, expression appeared to be
overwhelmingly from one parental allele. In two cases this was
associated with a clear allelic imbalance, which was phase miss-
matched in one case.
DISCUSSION
We have previously investigated the expression of a large number
of transcripts in primary tumour vs normal tissue by microarray
analysis (Heighway et al, 2002). Subsequently, by immunohisto-
chemistry, we and others have begun to examine in normal lung
tissue, preneoplastic lesions and primary tumours, the expression
patterns of genes that are strongly, and apparently (as determined
by RT–PCR) specifically, tumour expressed (Massion et al, 2003;
Smith et al, 2003, 2004). The derived data show that many NSCLCs
AURKB expression in lung cancer
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sTable 2 Microsatellite derived instability data: loci scored as allelically imbalanced were totalled in each group and compared
AURORA B:   COMPARATIVE MULTIPLEX
Marker Location 173 176 179 182 184 195 205 206 208 210 211 216 223 231 232 174 183 193 194 196 197 198 200 204 207 209 220 229 230 235
D13S153 13q14
D13S171 13q12.3 NI NI NI NI NI NI NI fail NI NI NI NI
D13S263 13q14 NI NI fail
D17S938 17p13.2 NI NI NI NI fail NI NI NI NI
D3S1263 3p26.1 NI NI NI NI NI
D3S1300 3p14.2 NI NI NI NI NI NI NI
D3S1566 3p26.1 NI NI NI NI NI NI NI fail
D5S644 5q15 NI NI NI fail NI
D9S157 9p22-p23 NI fail NI fail
D9S161 9p21 NI NI NI
lowest relative AURKB expression AI 42 67 highest relative AURKB expression
No AI 81 54
2x2 contingency table, Fishers exact test P = 0.0012
allelic imbalance
informative, no allelic imblance
NI none informative homozygote
fail PCR fail
REAL-TIME - AURORA A
Marker Location 235 176 179 229 184 193 205 206 208 196 211 216 223 231 232 173 195 210 182 174 183 194 197 198 200 204 207 209 220 230
D13S153 13q14
D13S171 13q12.3 NI NI fail NI NI NI NI NI NI NI NI NI
D13S263 13q14 fail NI NI
D17S938 17p13.2 NI NI NI NI NI fail NI NI NI
D3S1263 3p26.1 NI NI NI NI NI
D3S1300 3p14.2 NI NI NI NI NI NI NI
D3S1566 3p26.1 NI NI fail NI NI NI NI NI
D5S644 5q15 NI fail NI NI NI
D9S157 9p22-p23 fail NI NI fail
D9S161 9p21 NI NI NI
lowest relative AURKA expression AI 52 57 highest relative AURKA expression
No AI 69 66
2x2 contingency table, Fishers exact test P = 0.8
The top panels represent low and high relative expression of AURKB as determined by comparative multiplex RT–PCR. The lower panel represents those cases re-ranked into similar groups on the basis of AURKA expression.
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Genetics and Genomicsstrongly express particular genes, including certain cytokeratins,
which are characteristically expressed by the bronchial epithelial
basal cells (Smith et al, 2004). In turn, such observations suggest
that NSCLCs frequently derive from, share a common gene
expression pattern with or tend to differentiate towards the basal
cells. This cell type is a multipotent progenitor capable of renewing
the mature epithelial cells of the airway (Hong et al, 2004).
A central question when examining such gene expression data,
especially when as in most cases the expression pattern or even the
identity of the cell of origin of the tumour is not known, is whether
strong differential tumour expression in bulk tumour vs normal
analyses simply reflects the typical expression pattern of the (rare)
progenitor. In terms of the utility of a particular protein as a
diagnostic or drug target, the reason why a candidate gene is
strongly expressed in the tumour cell may be of secondary
importance compared to how specifically that gene is expressed by
the target cell and how vital that product is to host cell function.
However, if our aim is to identify genes that are causally driving
SERPINB5
Allelic imbalance Allelic expression imbalance
DNA cDNA
cDNA cDNA
L207 L198 L231 L289 L208 L207 L207 L198 L231 L289 L208
A2
A1
TTT TT M N T T T T T M
TERT 
TNTNTNTNTNTN
TNTNTNTNTNTN
| L61 |  194 | 209 |  227  | 230  | 235  |
DNA
cDNA
A1
A2
A2
M
89 75 530 57 817 4
A1
PRAME
A2
A1
MM NTNTNTNT TTTT
L141 L141 | | | L200 L200 L224 L224 L182 L182 MM
Figure 4 SERPINB5, PRAME and TERT allele-specific expression analyses and corresponding allelic imbalance measurements in matched primary tissues
from lung cancer patients. SERPINB5: Two examples of tumours showing marked AEI in the apparent absence of AI are shown (L61, 194). In the case of
L61, weak expression was seen in the matched normal tissue and this shows matching AEI. Patient 230 shows a phase matched AI and AEI in tumour tissue,
a balanced normal DNA sample, and an AEI favouring the other allele in the normal cDNA. All samples from patient 227 are balanced. Real time values for
over-representation of SERPINB5, relative to APPBP2 in the tumour over matched normal tissue are given below the image. PRAME: Three tumours
showing AEI are shown with only L224 having equal co-expression of both alleles. TERT: Telomerase subunit expression was not detected in any normal
lung tissue. 5 out of 5 informative samples analysed in duplicate runs showed expression strongly biased towards one parental allele.
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saspects of the neoplastic phenotype, then we need to identify those
sequences which are expressed inappropriately as a consequence
of induced DNA damage or erroneous epigenetic marking. Such
information may increase our understanding of the disease
process, guide future drug discovery or provide a rationale for
the use of particular drugs in particular diseases.
Following such arguments, this study was an attempt to examine
whether deregulation of aurora kinase genes, in particular AURKB,
was implicated in lung cancer development. We have shown that
AURKB is strongly expressed in exponentially proliferating
bronchial epithelial cells in culture and that this expression is
markedly reduced in confluent cells. We have also shown that
almost all tumours show higher levels of AURKB (and AURKA)
expression than their matched normal lung tissues, which could
therefore simply be a consequence of a higher proliferative index,
or be typical of the progenitor cell and atypical of the bulk of
normal lung cells. But crucially, we have provided evidence that
this expression is likely to be inappropriate given that in tumours
but not matched normal tissue, it is generally strongly biased
towards one parental allele. In many cases, this was associated with
a marginal allelic imbalance at the genomic locus and a marginal
increase in certain samples in locus copy number. As the in vitro
bronchial cell preparation used in our analysis was uninformative
for the cSNP, we could not confirm that the high level of gene
expression seen in actively growing normal cells was bi-allelic.
However, this conclusion is suggested by the analysis of AURKB
expression in normal lung tissue from informative patients,
where both alleles were expressed equally in each case. There are
a number of reasons why the high-level expression of a gene in
a tumour might occur predominantly from one of two genomically
balanced alleles. These include cis-located mutational or epimuta-
tional differences, chromosomal translocation and polymorphism
in tumour-utilised promoters or transcription factor binding
sites. Further investigations are required to determine the cause(s)
of the AEIs seen in AURKB and other genes implicated
in NSCLC.
Further to the allelic expression data, we were able to show that
patients with tumours expressing AURKB at the highest levels had
a shorter progression-free survival. This observation supports
the hypothesis that excessive AURKB expression is a marker for
aggressive tumour biology. However, it must be stressed that this
patient series is small and therefore this hypothesis must be viewed
with some caution. Additional studies on larger patient series will
be needed to more fully explore the role of AURKB expression as a
potential prognostic marker for NSCLC patients.
The aurora family (A, B and C) are serine threonine kinases.
Considerable attention is currently being given to the question of
whether these proteins might be effective anticancer drug targets
(for a review, Keen and Taylor, 2004). Genetic instability is a
common feature of solid tumours. The molecular changes that
lead to instability are imprecisely known, but are likely to involve
defects in the process of mitosis. The protein kinases of the aurora
family play a role in the regulation of mitosis from G2 through
to cytokinesis and are implicated in the maintenance of correct
chromosome number and accurate chromosome segregation.
Alterations to the balance of expression of these genes could
therefore have a role in cancer development through the
generation of chromosome instability.
Aurora A kinase binds the centrosome and mitotic spindle and
is involved in spindle assembly. Elevated expression has been
documented in breast, bladder, colon, ovarian and pancreatic
cancers (Zhou et al, 1998; Tanaka et al, 1999; Sen et al, 2002;
Li et al, 2003) and gliomas (Klein et al, 2004). It has further
been reported to correlate with invasive disease in breast cancer
(Tanaka et al, 1999) and genomic instability in breast cancer
(Miyoshi et al, 2001) and bladder cancer (Fraizer et al, 2004). The
gene is amplified in many cancers including breast, bladder,
heaptocellular and colorectal cancers and glioma and it has
recently been implicated as a cancer-susceptibility gene in mouse
and humans (Ewart-Toland et al, 2003). Forced expression of
aurora A kinase in NIH3T3 cells and diploid human breast
epithelial cells induced centrosome amplification and transforma-
tion in vitro and aurora A-transfected NIH3T3 cells formed
tumours when injected into nude mice (Zhou et al, 1998).
Aurora B kinase is a chromosomal passenger protein that
regulates chromosome segregation and cytokinesis. Its over-
expression has been reported in several human cancer cell lines
and in primary tumours including colorectal cancer (Bischoff et al,
1998), seminomas (Chieffi et al, 2004) and thyroid anaplastic
carcinoma (Sorrentino et al, 2005). Exogenous expression of
wild-type aurora B kinase in several tumour cell lines and in
normal diploid fibroblasts has been shown to induce multi-
nuclearity and aneuploidy (Tatsuka et al, 1998). Expression of
kinase defective aurora B has similarly produced multinuclear cells
resulting in cell-death (Terada et al, 1998).
The function of aurora C kinase is less well defined. The gene is
overexpressed in primary colorectal cancer and a variety of cell
lines (Kimura et al, 1999; Takahashi et al, 2000).
Anueploidy is one of the defining characteristics of malignant
cells. As aurora B kinase appears to have a critical role in ensuring
the accurate segregation of chromosomes at mitosis through the
destabilisation of syntelic (not under tension) attachments (Dewar
et al, 2004) and as Ota et al (2002) had shown in a model system
that forced expression the protein was linked to the generation of
aneuploidy, we examined whether tumours with high levels of
AURKB expression might show higher levels of genomic
instability. While our analysis was limited, this did indeed appear
to be the case. This raises an intriguing question: could early
deregulation of AURKB, resulting in either inappropriately high
levels of or else inappropriately timed expression of this protein be
a driver of chromosome instability in tumours? This is an
attractive hypothesis although the alternative explanation, that
tumours with higher levels of genetic instability might be those
which tend to show low level amplification (generating allelic
imbalance and perhaps AEI) and high levels of expression of
AURKB, cannot be discounted without further analysis. If
deregulation of AURKB expression is indeed an early event
promoting genetic instability, then anti aurora B kinase agents may
have application in the future not only in the treatment of
advanced invasive disease but also in the suppression of the
development of disease in high-risk patients (secondary chemo-
prevention).
As we have noted already, a number of microarray highlighted
tumour expressed genes are normally expressed by multipotent
components of the airway but not by their differentiated progeny.
For a number of these tumour-expressed genes, we have also
shown that at high frequency, expression in tumour tissue is
strongly biased towards one chromosomal allele. Taking SER-
PINB5 (encoding maspin) as a specific example, we reasoned that
the rare expression of such genes in histologically normal
differentiated cells and more commonly in preneoplastic lesions
(Smith et al, 2003) and tumours might be a consequence of a
failure to appropriately inactivate these sequences in differentia-
tion-committed progeny during the asymmetric division of
multi-potent cells (Heighway et al, 2004). SERPINB5 expression
in normal tissue is known to be controlled at least in part by
promoter methylation (Futscher et al, 2002). The common failure
to inactivate one or both alleles of a gene that is associated with
maintenance of stem cell multi-potentiality in a differentiating cell
(an event perhaps linked causally to preneoplasia) and main-
tenance of that imprint through tumorigenesis might explain our
data. However, given our observations concerning AURKB
deregulation in tumours and the association of high levels of
expression with genetic instability in those lesions, we must
consider the possibility that the segregation of epigenetically
marked chromatin is error prone in multipotent tumour
AURKB expression in lung cancer
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that process.
Elegant experimental evidence exists that a stem cell chromatin
strand is retained in the stem cell progeny of asymmetric divisions
(Cairns, 1975; Merok et al, 2002; Potten et al, 2002). It is therefore
likely that this strand retains the epigenetic marking associated
with the multipotent cell gene expression pattern. Correspon-
dingly, it would seem likely that a new epigenetic imprint
appropriate for differentiation-committed cell gene expression is
applied to the non-stem cell chromatin. If chromosomes were
miss-segregated to the wrong daughter during asymmetric
division, perhaps as a consequence of miss-regulated expression
of aurora B kinase, this might therefore lead to a blurring of gene
expression patterns with perhaps the retention of certain stem cell
characteristics by differentiation-committed daughter cells. Such
miss-segregation could conceivably be followed by chromosomal
recombination events that would generate a chromatin mosaic.
This hypothesis, which might explain many of the gene expression
and epigenetic chromatin modification patterns of malignant cells,
clearly requires extensive further testing.
We believe that this work represents the first comprehensive
analysis of the expression of AURKB in primary NSCLC. We
further believe that the study provides some measure of rational
justification for the testing of aurora B kinase inhibitors in the
treatment of invasive lung cancer.
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